Patient Satisfaction
Patient satisfaction surveys generally show high levels of satisfaction, especially among elective inpatients.
CCCC is working to improve patients' sense of involvement using the “Shared Decision Making" approach.
There is also a focus on optimizing the role of the Patient-Responsible Physician.
Adverse Events
Adverse events have been reported, primarily related to medication, patient identification, and equipment. Risk analyses and quality deviation reviews have been conducted to improve processes.
Efforts are underway to compile overall figures for the types and numbers of adverse events (AE) in CCCC.
Medication-related AEs are a particular focus area.
Staff must comply with the guideline: Dispensing and administration of medicines and the provision of free-of-charge medicines (VIP).
Compliance with Patient Rights
Relevant cancer care pathways have been reviewed (see Appendix 2).
Departments comply with maximum waiting times, apart from a few incidents due to human error. These were minor delays of a few days, and patients were informed.
Patient Pathways
Analysis of neutrophil levels (DEFIBRE) has been updated to allow faster and safer results.
A joint statement to SFR Radiology is in preparation to define quality goals for reporting times on evaluation responses—currently awaiting feedback.
Resources and Capacity
There have been no capacity challenges in CCCC.
A new analysis of linear accelerator capacity in the future eastern region is being planned.
Assessment
Results are generally satisfactory.
Audit outcomes in national databases are acceptable, although indicators are inconsistent and insufficient for oncology treatment.
CCCC aims to have more relevant indicators included in national databases for oncology care pathways.
Survival outcomes in CCCC are very satisfactory.
Going forward, focus should be placed on survival and toxicity in adjuvant immunotherapy treatment pathways.
There have been no breaches of patient safety, and patient satisfaction is considered satisfactory.
CCCC is planning a joint report on adverse events.